SCHEMBL2144182

SCHEMBL2144182

ClCC(Cc1ccccc1)C[SiH](Cl)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.40
TAAR1 Q96RJ0 4/20 0.38
SLC6A2 P23975 2/20 0.38
SIGMAR1 Q99720 2/20 0.38
MAOA P21397 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CYP2A6 P11509 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
CYP1A2 P05177 1/20 0.36
SLC18A2 Q05940 1/20 0.35
ANPEP P15144 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALPI P09923 1/20 0.34
PKM P14618 1/20 0.34
PTGS1 P23219 1/20 0.34
XIAP P98170 1/20 0.34
SLC7A5 Q01650 1/20 0.34
TRPA1 O75762 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27300743 0.83 EPHX1 (0.50) EPHX1TAAR1SLC6A2SIGMAR1MAOA
Ammonia Solution, Strong SCHEMBL29283276 0.81 EPHX1 (0.48) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL28177028 0.78 TAAR1 (0.37) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL353629 0.75 EPHX1 (0.48) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL22499343 0.75 EPHX1 (0.43) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL3883482 0.75 EPHX1 (0.43) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL28573244 0.75 TRPA1 (0.50) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL11821207 0.75 TRPA1 (0.47) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL27660444 0.75 TRPA1 (0.50) EPHX1TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL4981467 0.72 EPHX1 (0.60) EPHX1TAAR1SLC6A2SIGMAR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1985645-B1 Low molecular weight siloxanes with one functional group GELEST INC (US) 2017-03-15 EP disclosed
US-9528019-B2 Ultraviolet-curable inkjet composition and material SEIKO EPSON CORPORATION (JP) 2016-12-27 US disclosed
US-20160272833-A1 ULTRAVIOLET-CURABLE INKJET COMPOSITION AND MATERIAL SEIKO EPSON CORPORATION (JP) 2016-09-22 US disclosed
US-9422442-B2 Material including print layer produced by ultraviolet-curable composition SEIKO EPSON CORPORATION (JP) 2016-08-23 US disclosed
US-9416288-B2 Inkjet recording method SEIKO EPSON CORPORATION (JP) 2016-08-16 US disclosed
US-9382443-B2 Metal powder, ultraviolet-curable inkjet composition and recording material SEIKO EPSON CORPORATION (JP) 2016-07-05 US disclosed
WO-2016067584-A1 METHOD FOR MANUFACTURING THREE-DIMENSIONAL STRUCTURE, THREE-DIMENSIONAL STRUCTURE MANUFACTURING APPARATUS, AND THREE-DIMENSIONAL STRUCTURE SEIKO EPSON CORPORATION (JP) 2016-05-06 WO disclosed
US-20160009933-A1 MATERIAL INCLUDING PRINT LAYER PRODUCED BY ULTRAVIOLET-CURABLE COMPOSITION SEIKO EPSON CORPORATION (JP) 2016-01-14 US disclosed
US-9080069-B2 Composition for inkjet and recording material SEIKO EPSON CORPORATION (JP) 2015-07-14 US disclosed
US-20150145935-A1 INKJET RECORDING METHOD SEIKO EPSON CORPORATION (JP) 2015-05-28 US disclosed
US-20100298591-A1 ASYMMETRIC LOW MOLECULAR WEIGHT SILOXANES WITH ONE FUNCTIONAL GROUP GELEST, INC. (US) 2010-11-25 US disclosed
US-7799888-B2 Low molecular weight siloxanes with one functional group GELEST, INC. (US) 2010-09-21 US disclosed
EP-1428795-B1 SILSESQUIOXANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF CHISSO CORP (JP) 2009-07-22 EP disclosed
US-7449539-B2 Silsesquioxane derivative and production process for the same CHISSO CORPORATION (JP) 2008-11-11 US disclosed
US-20080269429-A1 LOW MOLECULAR WEIGHT SILOXANES WITH ONE FUNCTIONAL GROUP GELEST, INC. (US) 2008-10-30 US disclosed
EP-1985645-A2 Low molecular weight siloxanes with one functional group GELEST, INC. (US) 2008-10-29 EP disclosed
US-20070032454-A1 Silsesquioxane derivative and production process for the same JNC CORPORATION (JP) 2007-02-08 US disclosed
US-7169873-B2 Silsesquioxane derivatives and process for production thereof CHISSO CORPORATION (JP) 2007-01-30 US disclosed
US-20040249103-A1 Silsesquioxane derivatives and process for production thereof JNC CORPORATION (JP) 2004-12-09 US disclosed
EP-1428795-A1 SILSESQUIOXANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF CHISSO CORPORATION (JP) 2004-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298591-A1 ASYMMETRIC LOW MOLECULAR WEIGHT SILOXANES WITH ONE FUNCTIONAL GROUP ILK, LASP1, PCNA EPHX1 2370/4885TAAR1 3400/4885SLC6A2 4765/4885
US-20070032454-A1 Silsesquioxane derivative and production process for the same KCNQ1, KCNQ2, KCNQ5 EPHX1 145/4885TAAR1 2908/4885SLC6A2 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.